Jordan

Interview Transcript Jordan:
"Courage is important to me — to be strong enough to teach the other kids what to do and show them the right way, not the wrong way."

Rhonda (mother):
"Jordan was small for his age. He was below the height and weight for his age group. He was diagnosed with growth deficiency. But when I asked the doctor, I said, 'What can I do? I mean, when he gets to high school, he is going to be five feet tall.' The doctor mentioned that something to look into would be growth hormones.

I started seriously looking into Nutropin AQ® [somatropin (rDNA origin) injection], and when I brought it to Jordan's attention, he just, he was really excited. I was amazed with the results."

Jordan:
"I'm in the black belt level. That's my goal, to get my black belt and teach other kids."

Rhonda (mother):
"He was so happy that he wasn't the shortest in his classroom. And the best part was when we went to Disneyland. I was really excited because we'd been to Disneyland a lot, but this is like, a whole new world. And he was so excited when they said, 'Oh, you can go on; you can go on, son.' And he goes, 'Really, I meet the height?' And he says, 'Yeah!'"

Product Indication: Nutropin AQ is indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.

Nutropin AQ is also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin AQ therapy should be used in conjunction with optimal management of chronic renal insufficiency.

Nutropin AQ is also indicated for the long-term treatment of short stature associated with Turner syndrome.

Nutropin AQ is also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone-deficient short stature, defined by height SDS < -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Important Safety Information: Growth hormone (GH) should not be used for growth promotion in pediatric patients with closed epiphyses.

GH should not be used in patients with active proliferative or severe non-proliferative diabetic retinopathy.

In general, GH should not be used in patients with active malignancy. Any pre-existing malignancy should be inactive and its treatment complete prior to instituting therapy with growth hormone. GH therapy should be discontinued if there is evidence of recurring tumor activity. GH should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor.

GH should not be used to treat patients with acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure.

GH is contraindicated in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Unless patients with Prader-Willi syndrome also have a diagnosis of GH deficiency, Nutropin AQ and Nutropin are not indicated for the long-term treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.

Patients being treated with Growth Hormone (GH) should be informed of the potential benefits and risks associated with Growth Hormone therapy. Please see the full prescribing information for additional safety information.

Please see the full Product Information for additional safety information.

Individual results may vary.